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Abstract New screening possibilities become available at a
high rate, both useful and unsound possibilities. All
screening programmes do harm, and only few have more
advantages than disadvantages at reasonable cost. Horizon
scanning is needed to identify those few possibilities with
more pros than cons. Attunement is needed between actors
involved: scientists developing new high-throughput
screening techniques and treatment, health care workers,
patients and consumers and governmental agencies. The
product of a process of attunement may be a quality mark
as a norm for professional conduct, rather than legal
measures, as the field is moving fast. As actors may have
varying perspectives, a governance structure is needed to
develop an agenda that is agreed upon by all or most actors
involved. A standing committee might oversee the evaluation
of benefits and disadvantages in an integrated approach,
taking evidence, economics and ethics into account. A
proactive role of governmental agencies is needed to facilitate
agenda setting and attunement. Policy making has to be
transparent and open to stakeholder engagement.
Keywords Genetic screening.Clinical utility.
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Introduction
In 1957, the US Commission on Chronic Illness defined
screening as
The presumptive identification of unrecognized
disease or defect by the application of tests, exami-
nations or other procedures which can be applied
rapidly. Screening tests sort out apparently well
persons who probably have a disease from those
who probably do not. A screening test is not intended
to be diagnostic. Persons with positive or suspicious
findings must be referred to their physicians for
diagnosis and necessary treatment (Commission on
Chronic Illness 1957).
Screening in medicine differs from diagnostic health
care, where patients come to a physician because they
experience a health problem. High expectations exist on the
increasing possibilities for screening, involving both early
disease detection and early detection of avoidable disease
risk. In the first half of this paper, we will briefly sketch the
dynamics of the field in terms of technological develop-
ments (using newborn screening as an example), societal
changes and conceptual challenges. In the second part, we
will then discuss the need for a governance infrastructure to
M. C. Cornel (*):C. G. van El
Section Community Genetics, Department of Clinical Genetics
and EMGO Institute for Health and Care Research,
VU University Medical Center,
BS7, D423, PO Box 7057, 1007 MB Amsterdam,
The Netherlands
e-mail: mc.cornel@vumc.nl
M. C. Cornel
Center for Medical Systems Biology,
Leiden, The Netherlands
M. C. Cornel
Center for Society and Genomics,
Nijmegen, The Netherlands
W. J. Dondorp
Department of Health, Ethics and Society, Maastricht University,
Maastricht, The Netherlands
W. J. Dondorp
Research School CAPHRI, Maastricht University,
Maastricht, The Netherlands
J Community Genet (2012) 3:73–77
DOI 10.1007/s12687-011-0056-yattune the promises of technology, the needs of patients and
citizens, the responsibilities of governmental agencies and
the experiences and expectations of health care workers.
The paper is mainly based on a presentation given in
Lund, Sweden in the Genetics and Democracy series on the
5th of October 2009. The main source of the presentation is
a report of the Health Council of the Netherlands:
Screening: between hope and hype (2008). Two of the
authors (MC, WD) were involved in the preparation of this
report, respectively, as a member of the committee and of
the staff of the Health Council.
The dynamics of the field
The dynamics of the field is determined by several
overlapping factors. These include technological develop-
ments (genomics, imaging and related technologies) that
allow for improved testing possibilities both for diagnostics
and screening, demographic changes emphasising the need
for disease prevention in specific (e.g. ageing) populations,
societal developments informing the way screening is
perceived as a means of risk management and develop-
ments regarding how and to whom screening is offered that
challenge the classical definition of screening and the
delineation between care and prevention.
Technological developments allowing extended screening
programmes
Genetic screening can be performed in the different
phases of life, including shortly after birth. Newborn
screening (NBS) is an example of a health care setting
where recent changes took place in many countries. NBS
programmes have been developed to identify infants in
whom early diagnosis may avoid irreversible health
damage. In the Netherlands, a national newborn screen-
ing programme started with phenylketonuria in 1974,
followed by congenital hypothyroidism in 1981 and
congenital adrenal hyperplasia in 2000. As in many
other countries, the development of tandem mass
spectrometry (MS/MS) made it possible to screen for
several other diseases, especially metabolic conditions,
a n di n2 0 0 7 ,1 4d i s o r d e r sw e r ea d d e dt ot h ep r o g r a m m e .
Apart from developments in diagnostics such as MS/MS,
also medical research had improved the therapies for
severe diseases that affect newborns. The promises of the fast
developments in genomics, proteomics, metabolomics and
bioinformatics make it relevant to reconsider NBS pro-
grammes in many countries. An important question is the
governance of this dynamic field: Who sets the agenda for
reconsideration, who scans the horizon, and who decides?
Attunement is needed between researchers who develop new
technology,physicianswhotreatthepatientsandpublichealth
authorities who organise screening programmes in many
countries (Achterbergh et al. 2007). Also, nonprofit organ-
isations (www.marchofdimes.com) and organisations of
patients and parents (www.ncfs.nl/index.php?id=000184)
have actively engaged in the agenda setting.
In the Netherlands, the decision to extend NBS from 3 to
17 diseases was made by the Minister of Health after the
advice of the Health Council of the Netherlands (2005). The
committee that prepared the advice included experts in the
fields of paediatrics, gynaecology, biochemical chemistry,
genetics, public health, ethics and legislation. Advisors from
the Ministry of Health and patient and parents organisations
attended (some of) the meetings. The committee defined
three categories:
& Considerable, irreparable damage can be prevented
(category 1)
& Less substantial or insufficient evidence of the prevention
of damage to health (category 2)
& No prevention of damage to health (category 3)
For disorders in category 1, if a good screening test was
available, inclusion in the NBS programme would be
advised. For category 3, NBS would not be advised. For
category 2, different advices are conceivable. More research
was advised for cystic fibrosis, where especially the
specificity of the test was considered unsatisfactory. A
large-scale pilot study was performed since leading to a
proposal for a four-step screening procedure, and in 2010,
the inclusion of cystic fibrosis in NBS was advised (Health
Council of the Netherlands 2010). The publication of a
report including the argumentation and the use of the three
categories make the decision process and the governance
transparent to a high extent.
Societal developments: risk and responsibility
Scientific progress and technological innovation have
made new and better tests possible, but that alone does
not explain the dynamics in the area of screening
(Health Council of the Netherlands 2008). Health care
systems are changing in many countries. Traditionally,
medical professionals exercised the power to decide what
should be done, with government monitoring quality and
costs. New parties, including commercial players, have
emerged, and governments and insurance companies
increasingly stress cost-effectiveness. Sometimes, as in
the Netherlands, this is accompanied by a focus on market
incentives leading to a redefinition of roles and respon-
sibilities, also with regard to screening. According to the
official philosophy behind the politics of current health
care reform, the increasing involvement of the market is
intended to lead to a better quality and greater response to
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may be offered without proper validation or evidence-
based advice, as in the case of the so-called whole-body
scans (Al-Shahi Salman et al. 2007; Health Council of the
Netherlands 2008). Moreover, as a logical consequence of
addressing patients as ‘health care consumers’,t h e r ei sa
growing emphasis on the personal responsibility of
individuals to stay healthy and make an optimal use of
the opportunities for prevention (Schmidt 2007). From a
wider perspective, the rise of predictive and preventive
medicine fits in with what the German sociologist Beck
has termed a ‘risk culture’, meaning that the development
of a more secular society and the fading away of a
deterministic world view have made managing uncertainty a
structural element of our lives (Beck 1992). Companies
selling genetic tests direct to consumers may appeal to and
reinforce anxiety about potential risk through their advertise-
ments, while insurance companies may offer health checks
and preventive testing as a service to attract more clients. In
this modern risk culture with its increasing emphasis on
individual responsibility for health, many people are recep-
tive for the reassurance that they expect from screening, with
hardly any attention to the potential disadvantages that
screening may also have (Ransohoff et al. 2002; Schwartz
et al. 2004).
Redefining screening
The Health Council of the Netherlands report ‘Screening:
between hope and hype’ (2008) redefines screening as:
Screening (…) involves the medical examination of
individualswhoexhibitnohealthproblemswiththeaim
of detecting disease, or an hereditary predisposition to
disease, or risk factors that can increase the risk of
disease.
While screening has often been offered in public health
programmes, neither in the definition from 1957 men-
tioned previously nor in this definition the ‘systematic
offer’ is mentioned. In the described dynamic cultural
changes, opportunities for (genetic) screening develop in
new contexts. Apart from national population screening
programmes, public health care may offer screening to
specific groups at risk, private practitioners may offer
health checks and commercial parties may offer both
screening services direct to consumers and do it yourself
testing kits. A proper evaluation of the benefits and
disadvantages of screening possibilities has not always
been performed before these screening tests and pro-
grammes are made available, while it is certain that
disadvantages always also exist. Especially direct-to-
consumer tests have raised concern (European Society
of Human Genetics 2010).
Blurring boundaries of care and prevention
Genetic testing in individual client-focused health care is
done for diagnostic purposes, or because of increased
risk, for instance if a family member has a genetic
condition. Family testing offered systematically to all
individuals on a family tree that has been traced both
vertically and horizontally is a form of screening
(cascade screening) and is aimed at prevention (Health
Council of the Netherlands 2008). Screening for familial
hypercholesterolaemia, which is already carried out in the
Netherlands, is an example of this approach. Several other
monogenic subtypes of common disorders could profit
from a systematic cascade screening approach, especially
in cardiogenetics (hypertrophic cardiomyopathy, long QT
syndrome, arrythmogenic right ventricular dysplasia),
oncogenetics (breast and ovarian cancer caused by
BRCA1 and BRCA2 mutations, familial adenomatous
polyposis), hereditary nonpolyposis colorectal cancer and
diabetes (MODY subtypes, hemochromatosis) (Van El and
Cornel 2011). Newborn screening may start as a public
health screening programme, but can only be successful if
health care for the patients identified is well in place.
These are but a few examples of the blurring boundaries of
care and prevention. Funding in many countries differs
between screening programmes (often collectively funded
public health programmes) and diagnostic health care
(insurance), unless there is a national health care system.
Regulations and legislation may also differ. This makes
extension of screening programmes a matter of policy
change on various domains.
The need for a governance infrastructure
Given the dynamics of the field, there is an urgent need for a
governance infrastructure to attune the promises of technolo-
gy, the needs of patients and citizens, the responsibilities of
governmental agencies, the aspirations of commercial parties
and the experiences and expectations of health care workers.
In this connection, we use the term ‘governance’ as
referring to the idea of a non-traditional way of public
policy making, involving coordination of responsibilities
between government and societal stakeholder networks
rather than through classical hierarchical control (Mayntz
2003; Bennett et al. 2009).
The role of the government
Both encouraging sensible screening and protection against
unsound screening are the duties of the government. To
ensure that worthwhile screening is available to the
population, it can be decided to include certain screening
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field is changing fast, legislation to regulate or ban certain
forms of screening may not be the most suitable means of
protection against unsound screening offers. A fresh
approach may include
& A standing expert committee on a national level to
perform horizon scanning to identify new and promising
screening possibilities, and
& A quality mark for responsible screening, based on
scientific assessments of new developments and aimed
at promoting responsible provision and responsible
choices
Standing committee
A standing committee of independent experts could oversee
the entire sphere of screening, proactively assess new
developments on their merits, pick up on hiatuses in the
development of knowledge and identify the risks of
screening and produce comprehensible and accessible
public information (Health Council of the Netherlands
2008). It would have to follow an integrated approach,
assessing evidence, economics and ethics (Grosse et al.
2010). Several frameworks of screening criteria have
further elaborated the Wilson and Jungner (1968) criteria
developed for the World Health Organization in 1968.
Some of the elements need to be made more explicit, such
as the definition of a ‘good test’. An acceptable sensitivity
(more than 95%?), specificity (more than 99.99%?) and
positive predictive value (more than 1 in 4?) need cut-offs.
Evidence needed for evaluation includes whether early
treatment leads to less mortality, morbidity, loss of weight,
days in hospital, pain, suffering, etcetera and better quality
of life. Economical evaluation needs agreement on the most
relevant aspects of cost (cost of the programme compared
to all health care expenditure? Cost per QALY?). Ethical
aspects need to be discussed and agreed upon between
actors involved to help implement screening programmes in
an ethically sound way (for instance, with regard to NBS,
relevant aspects include informed consent, unintended
findings, information on carrier status). The balancing of
pros (longer and healthier life) and cons (false positives,
identification of mild forms) has to be part of health
technology assessment (Hofmann 2008). The application of
these frameworks demands evaluation before a decision is
made whether or not to screen, but also monitoring of the
performance of the programme once installed. Genetic
screening policies have often been determined by techno-
logical capability, advocacy and medical opinion rather than
through a rigorous evidence-based review process (Grosse
et al. 2010). Decision making should, however, take into
account the principles of ethics and opportunity costs. It is
imperative that screening policy development is transparent
and open to stakeholder engagement, not only from a
democratic point of view but also to be able to draw upon
the relevant knowledge of stakeholders.
Quality mark
To guard citizens against health damage from risky or
unsound forms of screening, it is a key to inform them
adequately. Consumers who want to buy a product can
inform themselves for instance by checking the Conformité
Européenne (CE) marking. The CE marking certifies that a
product has met EU consumer safety, health or environ-
mental requirements. However, in vitro diagnostic tests
used in health care presently often have to be assessed only
by the manufacturer to get CE marking. A more
informative quality mark would have to refer to the clinical
validity and clinical utility of both screening products and
services. It is very important that professional groups and
their scientific associations are closely involved in the
development and implementation of such a quality mark.
This will not happen spontaneously, but will have to be
actively encouraged by a powerful central body (Health
Council of the Netherlands 2008). A quality mark would
have to be based as much as possible on existing guidelines
and standards, while in turn the development of such
guidelines and standards could serve as a norm for
professional conduct, or even a ‘code of conduct’. The
existing schemes of quality control, accreditation or
certification, development of standards and recognition of
competence are available in several health care and
laboratory settings. Information to the public accompanied
with education of professionals, together with exposure of
both good and bad examples of screening practices, might
lead to public trust. Examples of quality marks or similar
developments can be found in the clinical utility gene cards
(Schmidtke and Cassiman 2010), EGAPP evaluation
(Evaluation of Genomic Applications in Practice and
Prevention (EGAPP) Working Group 2011), the activities
of the USA Food and Drug Administration to evaluate
direct-to-consumer genetic tests (Vorhaus 2011) and UK
Genetic Testing Network (Kroese et al. 2010).
Conclusion
A strong governance framework is needed to both
guarantee that sound screening is available and accessible
to the public, while citizens are protected against the risk of
unsound screening. A proactive role of governmental
agencies is needed to facilitate agenda setting and attune-
ment. Policy development should be transparent and open
to the engagement of all stakeholders involved. -
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